Unichem laboratories has announced the completion of Mrs. Priti Puri's term as Independent Director, effective March 20, 2026. The pharmaceutical company informed both the National Stock Exchange and BSE Limited about this board composition change under Regulation 30 of SEBI Listing Regulations.

Director Term Completion Details

The company disclosed that Mrs. Priti Puri's three-year tenure as Independent Director concluded on March 20, 2026. The Board of Directors acknowledged her contributions during her service period and extended best wishes for her future endeavors.

Revised Board Composition

Following Mrs. Priti Puri's term completion, Unichem Laboratories' board composition has been restructured effective March 21, 2026. The revised board comprises six directors across different categories.

Regulatory Compliance

The intimation was made in accordance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically under Regulation 30. The company provided all required details as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

The notification was signed by Pradeep Bhandari, Head – Legal & Company Secretary, ensuring proper regulatory compliance for the directorial change. The company maintains its governance structure with appropriate representation across executive and independent director categories.

Unichem Laboratories has announced its Q3 financial results, showing a remarkable turnaround in profitability driven by an exceptional gain. The pharmaceutical company reported strong profit growth despite operational challenges, with revenue declining and EBITDA margins under pressure during the quarter.

Financial Performance Overview

The company's Q3 performance was characterized by contrasting operational and bottom-line results. While core business metrics showed pressure, exceptional items significantly boosted overall profitability.

Exceptional Items Drive Profitability

The quarter's standout performance was driven by exceptional items totaling ₹275.52 crores in income. The company recorded a significant gain from the disposal of land and building at its erstwhile registered office, which more than offset operational challenges.

Operational Performance Analysis

Despite the exceptional gain, the company's core operational metrics showed continued pressure. Revenue from operations declined by 2.2% to ₹521.17 crores, while profit before exceptional items dropped significantly by 71% to ₹17.91 crores compared to ₹61.85 crores in the previous year.

Regulatory Filing and Compliance

The company has fulfilled its regulatory obligations by publishing its Q3 financial results in newspapers as required under Regulation 47 of the Listing Regulations. The results were published in the Mumbai edition of Business Standard and Mumbai Lakshdeep, Marathi Mumbai edition, ensuring compliance with stock exchange requirements.

Nine-Month Performance

For the nine months ended December 31, 2025, the company reported total comprehensive income of ₹244.76 crores compared to ₹83.85 crores in the corresponding previous period, reflecting the impact of exceptional items and improved operational performance over the extended period.